DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.